MedTrace Logo

VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia

NCT07536100 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-05-13

No results posted yet for this study

Summary

This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.

Conditions

  • Androgenetic Alopecia (AGA)

Interventions

DRUG

Topical minoxidil

Topical minoxidil solution applied to the scalp according to the study protocol for the treatment of androgenetic alopecia.

OTHER

Veneze peptide hair serum

Participants will apply the VENEZE peptide factor hair serum to the affected scalp areas twice daily for 24 weeks according to the study protocol

Sponsors & Collaborators

  • MEDEZE Cosmeceutical Company Limited

    collaborator UNKNOWN

  • Institute of Dermatology, Thailand

    lead OTHER_GOV

Principal Investigators

  • Chinmanat Lekhavat, MD, PhD · Institute of Dermatology

  • Suchanaree Laitrakul, MD · Institute of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-05
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07536100 on ClinicalTrials.gov